Journal of Antimicrobial Chemotherapy (2002) 49, 893-895
© 2002 The British Society for Antimicrobial Chemotherapy
Leading articles |
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
Department of Medical Microbiology, Faculties of 1Medicine and 3Pharmacy, University of Manitoba, Manitoba; Departments of 2Clinical Microbiology and 4Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada
Recently, there have been several reports of the dual activity of some fluoroquinolones used to treat infections probably caused by Streptococcus pneumoniae.1–3 Furthermore, there have been numerous declarations as to the clinical advantages of using dual-activity agents, including minimizing the development of resistance. These reports have been inconsistent, with fluoroquinolones being reported as having dual activity in some reports but not in others, and thus remain controversial.1,3–7 In order to clarify the reasons behind the inconsistencies, we have summarized the flaws of the methods by which the current data on the dual activity of fluoroquinolones against S. pneumoniae have been collected, and the conclusions that have been drawn. We offer suggestions of methods that may be used to clarify these reports of dual activity in the future, as well as a critical analysis of whether any truly dual-activity fluoroquinolones
 |
Footnotes |
|---|
|
References |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Cambau, S. Matrat, X.-S. Pan, R. Roth Dit Bettoni, C. Corbel, A. Aubry, C. Lascols, J.-Y. Driot, and L. M. Fisher Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli J. Antimicrob. Chemother., March 1, 2009; 63(3): 443 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Okumura, T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2008; 62(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Bhagwat, L. A. Mundkur, S. V. Gupte, M. V. Patel, and H. F. Khorakiwala The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3568 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Wang and M. Lipsitch Upgrading antibiotic use within a class: Tradeoff between resistance and treatment success PNAS, June 20, 2006; 103(25): 9655 - 9660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Davies, Y. C. Yee, R. Goldschmidt, K. Bush, D. F. Sahm, and A. Evangelista Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003) J. Antimicrob. Chemother., March 1, 2006; 57(3): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strahilevitz, A. Robicsek, and D. C. Hooper Role of the Extended {alpha}4 Domain of Staphylococcus aureus Gyrase A Protein in Determining Low Sensitivity to Quinolones Antimicrob. Agents Chemother., February 1, 2006; 50(2): 600 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Korzheva, T. A. Davies, and R. Goldschmidt Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2479 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strahilevitz and D. C. Hooper Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fisher, K. A. Gould, X.-S. Pan, S. Patel, and V. J. Heaton Analysis of dual active fluoroquinolones in Streptococcus pneumoniae J. Antimicrob. Chemother., August 1, 2003; 52(2): 312 - 313. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel Reply J. Antimicrob. Chemother., August 1, 2003; 52(2): 313 - 314. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fisher and V. J. Heaton Dual activity of fluoroquinolones against Streptococcus pneumoniae J. Antimicrob. Chemother., February 1, 2003; 51(2): 463 - 464. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel Reply J. Antimicrob. Chemother., February 1, 2003; 51(2): 464 - 465. [Full Text] [PDF]
|
|